Nordea Equity Research Reaffirms Sell Rating on AstraZeneca (AZN)
Other equities research analysts have also recently issued reports about the stock. Analysts at Societe Generale downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note to investors on Friday, December 14th. Separately, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Thursday, December 13th. They now have a $46.16 price target on the stock. Finally, analysts at JPMorgan Chase reiterated an “underweight” rating on shares of AstraZeneca in a research note to investors on Friday, December 7th. They now have a $47.66 price target on the stock.
Shares of AstraZeneca opened at 2984.00 on Friday. AstraZeneca has a one year low of GBX 2578.50 and a one year high of GBX 3116.50. The stock’s 50-day moving average is currently GBX 0.. The company’s market cap is £37.151 billion.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.